Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma

Takamasa Nakasuka; Eiki Ichihara; Go Makimoto; Yoshinobu Maeda; Katsuyuki Kiura

doi:10.1016/j.jtho.2019.03.009

Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma

Takamasa Nakasuka, Eiki Ichihara, Go Makimoto, Yoshinobu Maeda, Katsuyuki Kiura

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e168-e169
Journal	Journal of Thoracic Oncology
Volume	14
Issue number	8
DOIs	https://doi.org/10.1016/j.jtho.2019.03.009
Publication status	Published - Aug 2019

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.jtho.2019.03.009

Cite this

@article{57a53030664343e4a8bcc7cd710ba8b0,

title = "Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma",

author = "Takamasa Nakasuka and Eiki Ichihara and Go Makimoto and Yoshinobu Maeda and Katsuyuki Kiura",

year = "2019",

month = aug,

doi = "10.1016/j.jtho.2019.03.009",

language = "English",

volume = "14",

pages = "e168--e169",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "8",

}

TY - JOUR

T1 - Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma

AU - Nakasuka, Takamasa

AU - Ichihara, Eiki

AU - Makimoto, Go

AU - Maeda, Yoshinobu

AU - Kiura, Katsuyuki

PY - 2019/8

Y1 - 2019/8

UR - http://www.scopus.com/inward/record.url?scp=85069602416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069602416&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2019.03.009

DO - 10.1016/j.jtho.2019.03.009

M3 - Letter

C2 - 31345339

AN - SCOPUS:85069602416

SN - 1556-0864

VL - 14

SP - e168-e169

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 8

ER -

Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this